Collecting oral mucosa cells and/or cell fragments from patients, comprises chewing water insoluble, non-digestible chewing mass by the patient, adsorbing oral mucosa skin cells, DNA, RNA/their fragments by chewing mass and separating
DE102008057257A1
Collecting oral mucosal cells and/or -cell fragments from patients, comprises allowing patient to chew a water-insoluble, indigestible chewing mass, during which cells are absorbed in chewing mass and separating the cells from chewing mass
WO2007137864A1
Use of inhibitors of pp2c for treating or preventing arteriosclerosis
EP1754474A1
Use of S-Clenbuterol
JP2004018524A
Method for treating arteriosclerosis
AU2002333510A1
Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases
DE10226420A1
Procedure for the treatment of atherosclerosis
DE10222481A1
Contrast agent for use in imaging
DE10149611A1
Use of beta-adrenoceptor agonists, e.g. reproterol, salmeterol or terbutaline, for restoring and/or maintaining function of damaged nerve cells, e.g. for treatment of neurodegenerative diseases
DE10142175A1
Use of beta-adrenoceptor agonists, e.g. reproterol, salmeterol or terbutaline, for restoring and/or maintaining function of damaged nerve cells, e.g. for treatment of neurodegenerative diseases
DE10142176A1
Use of beta-adrenoceptor agonists, e.g. reproterol, salmeterol or terbutaline, for restoring and/or maintaining function of damaged nerve cells, e.g. for treatment of neurodegenerative diseases
DE10142178A1
Use of beta-adrenoceptor agonists, e.g. reproterol, salmeterol or terbutaline, for restoring and/or maintaining function of damaged nerve cells, e.g. for treatment of neurodegenerative diseases
DE10114352C1
New 4-phenyl- and 4-(4-substituted-phenyl)-n-butane-1-hydroxy-1,1-diphosphonic acids and per(trimethylsilyl) esters and known analogs are useful as targeted cytostatic drugs
DE10016559A1
System for the transport of active substances in a biological system
